This is a summary of the European public assessment report (EPAR) for Visudyne. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Visudyne.
Therapeutic Indication
Visudyne is indicated for the treatment of: * adults with exudative (wet) age\-related macular degeneration (AMD) with predominantly classic subfoveal choroidal neovascularisation (CNV) or; * adults with subfoveal choroidal neovascularisation secondary to pathological myopia.
Therapeutic Area (MeSH)
ATC Code
S01LA01
ATC Item
N/A
Pharmacotherapeutic Group
Ophthalmologicals
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| verteporfin | N/A | verteporfin |
EMA Name
Visudyne
Medicine Name
Visudyne
Aliases
N/ANo risk management plan link.
